Enviar artigo por via de e-mail Safe Use of Systemic Interferons for Multiple Sclerosis Treatment
- Autores: Snegireva I.I.1, Darmostukova M.A.1, Kazakov A.S.1, Lepakhin V.K.1
-
Afiliações:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- Edição: Volume 52, Nº 10 (2019)
- Páginas: 863-864
- Seção: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/245514
- DOI: https://doi.org/10.1007/s11094-019-1916-8
- ID: 245514
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.
Palavras-chave
Sobre autores
I. Snegireva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: SnegirevaII@expmed.ru
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051
M. Darmostukova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051
A. Kazakov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051
V. Lepakhin
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051
Arquivos suplementares
